Cargando…
Incidence and Outcomes of COVID-19 Infection in Heart Transplant Recipients: The USC Experience
PURPOSE: Heart transplant recipients may be at increased risk for infection and adverse outcomes from infection with coronavirus (Covid-19). Management of these patients is complex, with no standard of care. We sought to describe the incidence and outcomes of coronavirus infection in this unique pop...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979425/ http://dx.doi.org/10.1016/j.healun.2021.01.608 |
_version_ | 1783667282315051008 |
---|---|
author | Miklin, D. Lee, A. Rosen, B. Salimbangon, A. Cochran, A. Singhal, P. Miller, S. Saffarian, M. Onwuzurike, J. Kingsford, P. Li, J. Yang, K. Wolfson, A. Vaidya, A. Depasquale, E. |
author_facet | Miklin, D. Lee, A. Rosen, B. Salimbangon, A. Cochran, A. Singhal, P. Miller, S. Saffarian, M. Onwuzurike, J. Kingsford, P. Li, J. Yang, K. Wolfson, A. Vaidya, A. Depasquale, E. |
author_sort | Miklin, D. |
collection | PubMed |
description | PURPOSE: Heart transplant recipients may be at increased risk for infection and adverse outcomes from infection with coronavirus (Covid-19). Management of these patients is complex, with no standard of care. We sought to describe the incidence and outcomes of coronavirus infection in this unique population. METHODS: Retrospective review of 225 heart transplant patients at a large academic medical center identified 8 patients with laboratory confirmed Covid-19 infection. Laboratory and clinical data were collected from our institution as well as other local hospitals patients had been treated at. Outcomes were followed from March 15, 2020 to October 15, 2020. All data was deidentified. RESULTS: In a cohort of 225 heart transplant patients, 8 patients were identified after testing positive for Covid-19 infection. The mean and median age of patients was 49.8 and 42 years respectively. 63% of patients were male, and 37% of patients were female. The median and mean time from transplant to diagnosis was 4.1 and 4.5 years. The rate of infection for recently transplanted patients was 11%. Two patients (25%) had atherosclerosis, three patients (37.5%) had diabetes, and five patients (62.5%) had hypertension. Four of the patients (50%) were asymptomatic, 3 patients (37.5%) had acute hypoxic respiratory failure, and 1 patient (12.5%) had dyspnea not requiring oxygen at time of presentation. Four patients (50%) were admitted for treatment. Two patients were treated with remdesvir, one patient with tocilizumab, and one patient with lenrolimab. Immunosuppressive regimens were altered in five patients with decreased mycophenolate mofetil dosing, two patients with decreased tacrolimus dosing, and one patient with decreased cyclosporine dosing. Two patients (25%) had evidence of graft injury with mean AlloSure (donor derived cell free DNA) of 0.6%, the remainder were within normal limits. Overall our patient experience resulted in zero mortality, and all 4 admitted patients were discharged home safely. CONCLUSION: In a single center case series 8 patients were identified with Covid-19 infection. 25% of the patients demonstrated evidence of graft injury, and nearly every patient had their immunosuppressive regimen decreased with 100% survival to date. Further investigation is needed to determine long term outcomes and ideal therapeutic regimen for Covid-19 in this unique population. |
format | Online Article Text |
id | pubmed-7979425 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79794252021-03-23 Incidence and Outcomes of COVID-19 Infection in Heart Transplant Recipients: The USC Experience Miklin, D. Lee, A. Rosen, B. Salimbangon, A. Cochran, A. Singhal, P. Miller, S. Saffarian, M. Onwuzurike, J. Kingsford, P. Li, J. Yang, K. Wolfson, A. Vaidya, A. Depasquale, E. J Heart Lung Transplant (494) PURPOSE: Heart transplant recipients may be at increased risk for infection and adverse outcomes from infection with coronavirus (Covid-19). Management of these patients is complex, with no standard of care. We sought to describe the incidence and outcomes of coronavirus infection in this unique population. METHODS: Retrospective review of 225 heart transplant patients at a large academic medical center identified 8 patients with laboratory confirmed Covid-19 infection. Laboratory and clinical data were collected from our institution as well as other local hospitals patients had been treated at. Outcomes were followed from March 15, 2020 to October 15, 2020. All data was deidentified. RESULTS: In a cohort of 225 heart transplant patients, 8 patients were identified after testing positive for Covid-19 infection. The mean and median age of patients was 49.8 and 42 years respectively. 63% of patients were male, and 37% of patients were female. The median and mean time from transplant to diagnosis was 4.1 and 4.5 years. The rate of infection for recently transplanted patients was 11%. Two patients (25%) had atherosclerosis, three patients (37.5%) had diabetes, and five patients (62.5%) had hypertension. Four of the patients (50%) were asymptomatic, 3 patients (37.5%) had acute hypoxic respiratory failure, and 1 patient (12.5%) had dyspnea not requiring oxygen at time of presentation. Four patients (50%) were admitted for treatment. Two patients were treated with remdesvir, one patient with tocilizumab, and one patient with lenrolimab. Immunosuppressive regimens were altered in five patients with decreased mycophenolate mofetil dosing, two patients with decreased tacrolimus dosing, and one patient with decreased cyclosporine dosing. Two patients (25%) had evidence of graft injury with mean AlloSure (donor derived cell free DNA) of 0.6%, the remainder were within normal limits. Overall our patient experience resulted in zero mortality, and all 4 admitted patients were discharged home safely. CONCLUSION: In a single center case series 8 patients were identified with Covid-19 infection. 25% of the patients demonstrated evidence of graft injury, and nearly every patient had their immunosuppressive regimen decreased with 100% survival to date. Further investigation is needed to determine long term outcomes and ideal therapeutic regimen for Covid-19 in this unique population. Published by Elsevier Inc. 2021-04 2021-03-20 /pmc/articles/PMC7979425/ http://dx.doi.org/10.1016/j.healun.2021.01.608 Text en Copyright © 2021 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | (494) Miklin, D. Lee, A. Rosen, B. Salimbangon, A. Cochran, A. Singhal, P. Miller, S. Saffarian, M. Onwuzurike, J. Kingsford, P. Li, J. Yang, K. Wolfson, A. Vaidya, A. Depasquale, E. Incidence and Outcomes of COVID-19 Infection in Heart Transplant Recipients: The USC Experience |
title | Incidence and Outcomes of COVID-19 Infection in Heart Transplant Recipients: The USC Experience |
title_full | Incidence and Outcomes of COVID-19 Infection in Heart Transplant Recipients: The USC Experience |
title_fullStr | Incidence and Outcomes of COVID-19 Infection in Heart Transplant Recipients: The USC Experience |
title_full_unstemmed | Incidence and Outcomes of COVID-19 Infection in Heart Transplant Recipients: The USC Experience |
title_short | Incidence and Outcomes of COVID-19 Infection in Heart Transplant Recipients: The USC Experience |
title_sort | incidence and outcomes of covid-19 infection in heart transplant recipients: the usc experience |
topic | (494) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979425/ http://dx.doi.org/10.1016/j.healun.2021.01.608 |
work_keys_str_mv | AT miklind incidenceandoutcomesofcovid19infectioninhearttransplantrecipientstheuscexperience AT leea incidenceandoutcomesofcovid19infectioninhearttransplantrecipientstheuscexperience AT rosenb incidenceandoutcomesofcovid19infectioninhearttransplantrecipientstheuscexperience AT salimbangona incidenceandoutcomesofcovid19infectioninhearttransplantrecipientstheuscexperience AT cochrana incidenceandoutcomesofcovid19infectioninhearttransplantrecipientstheuscexperience AT singhalp incidenceandoutcomesofcovid19infectioninhearttransplantrecipientstheuscexperience AT millers incidenceandoutcomesofcovid19infectioninhearttransplantrecipientstheuscexperience AT saffarianm incidenceandoutcomesofcovid19infectioninhearttransplantrecipientstheuscexperience AT onwuzurikej incidenceandoutcomesofcovid19infectioninhearttransplantrecipientstheuscexperience AT kingsfordp incidenceandoutcomesofcovid19infectioninhearttransplantrecipientstheuscexperience AT lij incidenceandoutcomesofcovid19infectioninhearttransplantrecipientstheuscexperience AT yangk incidenceandoutcomesofcovid19infectioninhearttransplantrecipientstheuscexperience AT wolfsona incidenceandoutcomesofcovid19infectioninhearttransplantrecipientstheuscexperience AT vaidyaa incidenceandoutcomesofcovid19infectioninhearttransplantrecipientstheuscexperience AT depasqualee incidenceandoutcomesofcovid19infectioninhearttransplantrecipientstheuscexperience |